Ischemic stroke is characterized as a cerebral vascular disease that is initially resulting from disruptions in cerebral blood circulation (often due to vascular occlusion) and can ultimately leads to brain tissue damage and cognitive as well as physical impairment (Campbell et al., 2019). Clinically, ischemic stroke manifests primarily as a sudden-onset focal or diffuse neurological deficit which are contributed by numerous etiological factors, exhibiting complex pathophysiological mechanisms across various biological scales. At the cellular and tissue levels, stroke onset and ischemia trigger substantial release of inflammatory cytokines and danger signals from dead cells, which can permeate surrounding tissues and activate inflammatory pathways within cells (Anrather and Iadecola, 2016). This typically involves pivotal receptor-mediated pathways such as TLRs (toll like receptors), TNFRs (tumor necrosis factor receptors), IFNRs (interferon receptors), and various interleukin receptors (Caso et al., 2007; Qin et al., 2022; Xue et al., 2022; Zhu et al., 2022; Kuo et al., 2023). Another essential regulator induced by ischemia is the activation of the HIF (hypoxia-inducible factor) pathway within brain tissues (Luo et al., 2022). The cascade of events downstream of HIF can contribute to angiogenesis, cell survival, and proliferation, thereby playing a vital role in the restoration of damaged brain tissue (Amalia et al., 2020). Ischemia also results in metabolic disturbances in brain cells, hampers the normal functioning of ion pumps which can disrupt intracellular ionic balance and activate pathways leading to cell apoptosis or necrosis (Sekerdag et al., 2018). On the brain microvasculature, the differential regulation of VEGF (vascular endothelial growth factor) pathway is pivotal in regulating angiogenesis, vascular permeability and blood-brain barrier remodeling (Greenberg and Jin, 2013). Following the restoration of blood flow, ischemia-reperfusion injury can occur and further exacerbate the condition due to excessive production of reactive oxygen species (ROS), calcium overload, damage to gap junctions, metabolic dysregulation, and mitochondrial dysfunction (Nour et al., 2013; Al-Mufti et al., 2018; Gauberti et al., 2018). Further at the human body system level, variations in genetics, age, gender, health status, and lifestyle among different patients can result in divergent disease progression and recovery trajectories and this necessitates the investigation of personalized treatment strategies (Zafar et al., 2016). Overall, the complexity of ischemic stroke pathophysiology is at least multi-scale from sophisticated signal transduction and crosstalk at the cellular level, to multi-faceted pathogenic and tissue damage mechanisms at the tissue level, all the way to interindividual variability at the systems level, and this has posed significant challenges to traditional experimental research that aims to identify drug targets and treatment plans given the extremely low success rates of stroke clinical trials in the past two decades (Chen and Wang, 2016; Dhir et al., 2020).

Computational systems biology modeling, grounded in physiology- and data-driven computer simulations, has emerged as a robust and high-throughput approach for interpreting and analyzing complex pathophysiological processes (Kitano, 2002). These computational models have their unique advantages in basic research and drug development as they allow mechanistic integration of multimodal biological knowledge and data across scales and studies (Yue and Dutta, 2022; Zhang et al., 2022), and for complex diseases such as ischemic stroke, the systems-level understandings derived from such models could contribute significantly in translational research. As biological systems are dynamical, ordinary differential equation (ODE) modeling has become one of the most prevalent computational modeling approaches in the field, with a long history originating from the study and simulation of biochemical pathways and gene regulatory networks (Sordo Vieira and Laubenbacher, 2022). A major advantage of ODE modeling is that the ODE model system can be mechanistically constructed and explained given a priori knowledge regarding how various system components (e.g., genes, proteins, cells) interact with each other, and the mathematical solution of the ODE system can quantitatively predict time-course profiles of the entire system behavior (including all components) upon particular perturbations which can physiologically mimic disease triggers (Daun et al., 2008). Other modeling approaches besides ODE such as agent-based modeling, logic-based modeling, partial differential equation (PDE) modeling as well as hybrid modeling have also gained popularity in different research fields. PDE modeling, given its strong theoretical basis in physical principles such as mass transfer and reaction-diffusion, are particularly useful in the simulation of biophysical processes such as vascular blood flow (Caiazzo et al., 2018). Thus, considering the disease features of ischemic stroke, ODE and PDE modeling (sometimes used in hybrid) are commonly employed by computational systems biologists to decipher intracellular signal transduction, cell-cell interaction as well as vascular hemodynamics in stroke translational research.

In this review, we explore the application of computational systems biology modeling in ischemic stroke research across various scales, including cellular, tissue, and human body levels (Figure 1). We will also touch upon recent examples that employed multi-omics and network pharmacology approaches for therapeutic target identification and biomarker evaluation in ischemic stroke. We emphasize the role of these modeling analyses in elucidating the complex intracellular signaling patterns in brain cells and the dynamic spatiotemporal changes in brain tissue damage and repair following ischemic stroke, as well as the utilization of computational models to predict individual stroke patient outcome and formulate personalized treatment plans (Table 1; Table 2).

The concept of the Neurovascular Unit (NVU) was introduced in 2001 at a meeting of the National Institute of Neurological Disorders and Stroke as the fundamental unit for studying the mechanisms of interaction between neural and vascular components (Wang et al., 2021; Tiedt et al., 2022). Structurally, the NVU encompasses neurons, glial cells (e.g., astrocytes, microglia), endothelial cells, smooth muscle cells and pericytes. Functionally, the NVU mediates neurovascular coupling (NVC), wherein neurons and astrocytes secrete substances to regulate cerebral blood flow (CBF) (Salinet et al., 2019; Beishon and Minhas, 2021) as well as ensure adequate energy supply and timely clearance of metabolic by-products. NVU also coordinates the formation of the blood-brain barrier (BBB) through the regulation of endothelial cells and pericytes, which is responsible for preventing the entrance of metabolic toxins and safeguarding normal neural functions (Salmina et al., 2021; Naranjo et al., 2022). Following the onset of ischemic stroke, the blood-brain barrier is compromised, resulting in increased permeability which allows metabolic by-products to infiltrate the central nervous system and cause damage to neural cells (Abbott et al., 2010; Prakash and Carmichael, 2015). Subsequently, impaired neural cells exhibit reduced capacity to regulate CBF which results in the accumulation of metabolic waste and accelerates the progression of the disease. Therefore, maintaining the functional integrity of NVU during ischemic stroke is crucial for preserving brain function and mitigating brain injury. Previous studies have demonstrated that mechanistic systems biology modeling can provide a robust framework to describe and analyze complex multiscale biological systems; in the scenario of NVU, this could greatly advance our understanding of the emergent underlying principles that govern the operation of NVU. The subsequent section will discuss mechanism-based computational models specifically developed for the various cellular components of NVU, including astrocytes, microglia, brain microvascular endothelial cells and neurons.

Ischemic stroke at the tissue level involves the complex interplay of excitotoxicity, oxidative stress, inflammation, and endothelial damage (Culmsee and Krieglstein, 2007; Amantea et al., 2009). Excitotoxicity, a process involving neurons and astrocytes, is exacerbated under hypoxic conditions due to the excessive release of glutamate by neurons and reduced glutamate absorption by astrocytes. This glutamate surplus overstimulates NMDARs, leading to calcium influx and activation of calcium-dependent death signal proteins, ultimately resulting in neuronal death (Belov Kirdajova et al., 2020; Shen et al., 2022). In the acute phase, oxidative stress will lead to significant production of ROS and cause primary tissue damage. During reoxygenation, peripheral immune cells can also contribute to oxidative stress by enhancing iNOS (inducible nitric oxide synthase) expression and the formation of oxidizing peroxynitrite which would further result in nitrosative stress and cell damage (Crack and Taylor, 2005; Allen and Bayraktutan, 2009). The inflammatory response in stroke is usually a two-step process: the activation of immune cells within the brain, then followed by the recruitment of peripheral immune cells. Key players in this process include microglia, astrocytes, neutrophils, and macrophages, which secrete inflammatory cytokines, chemokines and engage in phagocytosis of dead cells. Under ischemic conditions, DAMPs (damage-associated molecular patterns) will activate microglia, altering their morphology and function to enhance phagocytosis and secretion of various cell factors and chemokines. These cell factors lead to the accumulation of adhesion molecules on the endothelium, paving the way for peripheral immune cells to enter brain tissue (Jin et al., 2010; Jayaraj et al., 2019). The second phase involves the infiltration of peripheral immune cells, primarily neutrophils and monocytes. These mechanisms will compromise the integrity of the blood-brain barrier, as endothelial cells interconnected by tight junction proteins becomes more permeable. This increased permeability allows molecules and ions from reperfused blood, including plasma proteins, salt, and water, to enter the tissue space. After tPA (tissue plasminogen activator) treatment and clot breakdown, restoration of blood flow to ischemic areas, coupled with increased blood pressure, can result in excessive fluid leakage into the tissue space. This fluid accumulation, particularly in cells, can lead to cytotoxic edema and cerebral edema that may escalate intracranial pressure and tissue stress. Furthermore, the unregulated movement of ions due to permeability changes can alter osmotic pressure, exacerbate edema accumulation and cause cellular acidosis. Severe BBB damage can also allow direct blood entry into brain tissue, forming hematomas and exerting further pressure on surrounding brain tissue (Kim et al., 2012; Huang et al., 2021).

To systematically understand this inflammation cascade, a study by Lelekov-Boissard et al. (2009) examines the dynamics of various types of cells post-stroke, including live and dead neurons, microglia cells, neutrophils, and macrophages. The categorization of more specific cell states involves alive/necrotic/apoptotic neurons, along with activated and resting microglia cells. Employing six ordinary differential equations, the model investigates the inflammatory response within the first 24 h following a stroke. The authors used this model to track changes in cell counts, pro-inflammatory factor levels, infiltration rates of neutrophils and macrophages into brain tissue, spatial and temporal activation of microglia cells, and the effects of phagocytosis. Model simulations suggested that the influx of neutrophils and macrophages into brain tissue are not simultaneous, indicating the need to treat these cells as distinct cell populations with different functions. Additionally, the model suggests incorporating spatial diffusion aspects such as the migration of chemotactic cells from blood to brain tissue and the diffusion of cytokines and chemokines, along with other aspects to be refined by future efforts (e.g., protective elements like complement cascades, endothelial growth factors, neurotrophic factors). In a similar attempt, Di Russo et al. (2010) proposed a hybrid ODE-PDE computational model that intricately involves neurons, astrocytes, microglia, neutrophils, macrophages, cytokines, and chemokines. The model incorporates the following pathophysiological processes during an ischemic stroke: neurons and neuroglial cells undergoing necrosis or apoptosis, cellular demise that activates microglia, activated microglia phagocytose dead cells and produce cytokines and chemokines, and macrophages and neutrophils infiltrating the brain tissue. This model employs 13 equations to simulate the alteration in tissue cell counts (particularly apoptotic and necrotic ones), expression of adhesion factors, as well as level of inflammatory mediators and chemokines over the first 72 h post-stroke. The authors simulated how size of the initial infarction can affect the process of inflammation, and the results showed that the severity of inflammation does not correlate linearly with the infarction size. This finding can help determine the optimal timing of using anti-inflammatory drugs during treatment, as the model suggested that the existence of tissue inflammation may be beneficial when the infarction size is small, and the use of anti-inflammatory drugs in small infarctions may actually exacerbate tissue damage in the long run. However, this conclusion may be driven by the biased model inclusion of primarily M1-type microglia and pro-inflammatory cytokines, as the potential anti-inflammatory M2 microglia response which was not described could also have profound impact on the regulation of drug treatment response.

In terms of BBB research, Orlowski et al. (2011) developed a mechanistic model that focuses on three mechanisms: fundamental brain cell metabolism, pH regulation, and increased H⁺ ions due to ATP consumption during a stroke. The metabolism module encompasses energy exchanges between neurons and astrocytes and nutrient transport via capillaries, while pH regulation involves a cellular buffering system with HCO₃ ^−, (CO₃)^2-, and H₂CO₃. The model equations for ATP consumption were formulated quantitatively based on Na⁺ concentration. Model simulations revealed a decrease in H⁺ concentration across neurons, astrocytes, and tissues with reduced cerebral blood flow upon stroke occurrence. To further describe in detail the impact of cerebral blood flow on H⁺ diffusion during ischemia and the roles of cellular ion pumps, in a follow-up work, Orlowski et al. (2013) added ion dynamics that were used to simulate cytotoxic edema and analyze dynamic changes in sodium, potassium, calcium, chloride, and bicarbonate ion concentrations. This new hybrid ODE-PDE model elucidates the evolution of spatial dimensions of neurons, astrocytes and the extracellular space during ischemia, focusing particularly on the impact of sodium ion and metabolite diffusion on cellular volume and subsequent tissue volume changes. Still, this model framework of post-stroke pH dynamics could be augmented in future with additional mechanisms (e.g., more details of chloride and hydrogen ion channels) to enhance its accuracy and predictive capability. From another perspective, Mokhtarudin and Payne (2015) developed a PDE-based model to analyze the impact of reperfusion on the disruption of the blood-brain barrier and the collapse of brain microvessels. This model quantitatively used the filtration of capillaries to simulate the formation of vasogenic edema and used morphological changes in microvessels to study their collapse. The simulation results suggested that microvessel collapse would happen most likely under high reperfusion pressure, low blood osmolarity, decreased blood-brain barrier reflection coefficient, and reduced microvessel stiffness. In terms of model limitations, the role of aquaporin-4, which is crucial in blood-brain barrier stabilization and modulation of brain edema, and arguably the effect of oxidative stress-induced damage on BBB should be considered in a future version, as mentioned by the authors.

Thrombolytic therapy and mechanical thrombectomy are the principal therapeutic interventions for ischemic stroke. The primary aim of these treatments is to re-establish blood flow by pharmacologically dissolving or surgically removing the vascular occlusion, thereby restoring perfusion and expediting the functional recovery of ischemic tissues (Green and Shuaib, 2006; Diener et al., 2013; Catanese et al., 2017). Currently, recombinant tissue plasminogen activator (rt-PA) is the only thrombolytic agent approved by the FDA for the treatment of ischemic stroke. Its primary mechanism of action involves converting plasminogen to plasmin, which degrades fibrin within thrombi, facilitating thrombolysis and restoring blood supply to the ischemic regions of the brain. However, the therapeutic window for rt-PA is narrow; administration beyond 4.5 h post-onset not only diminishes its efficacy but also increases the risk of hemorrhagic complications (Coutts et al., 2018; Hacke et al., 2018; Katsanos et al., 2021). Mechanical thrombectomy primarily targets large vessel occlusions, such as those in the middle cerebral artery, rapidly restoring blood flow and preventing extensive cerebral ischemia (Guo and Miao, 2021). Both therapeutic approaches carry inherent risks. Thrombolytic therapy in patients with underlying conditions such as hypertension or coagulation disorders can increase the risk of hemorrhage and may also lead to complications such as infections or recurrent strokes. Various external factors can lead to variability in the outcomes of mechanical thrombectomy, including the size and location of the thrombus, the duration of ischemia, and the patient’s specific physiological condition. Not all patients may experience a restoration of normal cerebral function postoperatively (Lambrinos et al., 2016; Jadhav et al., 2021). Assessing a patient’s indications for surgery is a highly challenging task, necessitating a comprehensive analysis of multiple baseline physiological indices (Mokin et al., 2019; Sarraj et al., 2023). Computational systems biology models can significantly aid in this complex task. By constructing virtual patient models using data from prior research, such an approach can support thrombectomy at multiple time points: preoperatively, individualized physiological data can be used to simulate and analyze potential post-surgical risks, aiding in the determination of a patient’s suitability for surgery; intraoperatively, simulations of different thrombectomy strategies can help maximize brain function preservation and increase the survival rate of brain tissue; postoperatively, these models can assist in devising subsequent treatment plans, enhancing the safety of the therapy and accelerating disease recovery (Table 2).

In a recent publication regarding the INSIST project (IN-Silico trials for treatment of acute Ischemic STroke), a systematic approach was reported in terms of constructing virtual patient models for ischemic stroke to enable prediction of therapeutic outcomes for different patients (Konduri et al., 2020). To systematically simulate blood flow, thrombectomy, brain tissue damage and clinical outcome of acute ischemic stroke (AIS) patients, different computational modules were developed and seamlessly connected under the INSIST modeling workflow. Firstly, a virtual cohort was generated using a variety of collected clinical data, including imaging and thrombus characteristics. Secondly, a biophysics-based computational modeling framework was designed and employed to simulate cerebral blood flow, perfusion, thrombosis, and mechanical thrombectomy at the individual patient level. As seen in a proof-of-concept study by Jozsa et al. (2021), an exemplar PDE-based three-compartment porous microcirculation model capable of describing changes in cerebral blood flow perfusion in both healthy individuals and ischemic stroke patients were computationally implemented, which was validated against CT imaging data from both healthy individuals as well as ischemic stroke patients. For thrombectomy, a PDE-based simulation strategy as described by Luraghi et al. (2021b) incorporates a physics-derived cohesive zone model that describes the viscoelastic properties of the thrombus-artery interface to enable accurate predictions of blood flow profiles following thrombectomy in ischemic stroke patients. In addition, such biophysics-driven modules are designed to be integrated with mechanism-based hypoxic tissue injury modules (for example, the hybrid ODE-PDE modeling work by Orlowski et al. (2013) as described in the second section of this review) to depict damage caused by hypoxia and reperfusion to cells and brain tissue, which would allow a more dynamic multiscale reflection of the pathophysiological processes during stroke initiation and progression.

The third step involves establishing connections and associations between physiological outputs generated from the biophysical models with actual clinical endpoints and outcome indicators for every patient. Finally, the aforementioned biophysical modeling-clinical outcome prediction system will be validated against unused clinical trial data to examine its predictability and applicability at the population level for clinical scenarios. As such virtual patient models include comprehensive depictions of the cerebral vasculature and are grounded in hemodynamics and the morphology of blood vessels and incorporate the actual location of occlusions to position virtual thrombi, they can provide high-throughput, comprehensive portrayal of the alterations in global cerebral blood flow that occur during ischemic stroke and upon surgery for every single patient. This can lead to the derivation of virtual clinical indicators, which would have great potential in formulating precise personalized patient treatment plans. The significant translational value of such in silico ischemic stroke trial studies following the above four steps proposed by the INSIST project has been first demonstrated in the publications by Miller et al. (2021), Miller et al. (2023). After integrating the various biophysical and physiological modules as described above, the authors, using their computational workflow, generated 500 virtual patients with M1 segment vessel occlusion, based on data of patients enrolled in the MR CLEAN Trial (Jansen et al., 2018). Following simulated endovascular treatment in all virtual patients, the population-level recanalization rate as predicted by the computational platform matched quantitatively with the reported trial results of MR CLEAN. The authors also explored different trial scenarios including thrombectomy in stroke patients with different thrombi fibrin compositions as well as performance comparison of different commercially available stent retrievers, demonstrating that such in silico trials can have a great potential to guide ischemic stroke clinical trial design and patient stratification as well as inform medical device developers on the design and performance of new thrombectomy devices.

Omics research entails a comprehensive analysis of biological molecules through the collective study of various biological datasets (Krassowski et al., 2020). Omics research methodologies encompass genomics, transcriptomics, proteomics, and metabolomics, among others, facilitating an in-depth understanding of molecular mechanisms at various biological levels, disease pathogenesis, and therapeutic targets for drug treatment (Hasin et al., 2017; Rohart et al., 2017; Durufle et al., 2021). Genomic studies focus on studying the entire genome of organisms. By examining the genome of stroke patients, it can identify the genetic variations that most significantly impact ischemic stroke and elucidates the relationship between different gene phenotypes and disease risk (Cheng et al., 2023). Transcriptomic studies primarily investigate the process by which genes are transcribed into mRNA. By analyzing changes in gene expression in patients with ischemic stroke, it identifies key gene modulators critical to the disease’s onset and progression, thereby discovering valuable molecular biomarkers for early diagnosis and prognosis prediction (Appunni et al., 2022; Gallego-Fabrega et al., 2022). Proteomics studies analyze the types, quantities, and functions of different proteins within biological samples. It has significant potential in identifying protein biomarkers in blood for stroke early diagnostics, therapeutic efficacy assessment and drug discovery (Gu et al., 2021; Hochrainer and Yang, 2022; Kalani et al., 2023). Metabolomic studies focus on the types and quantities of metabolites within organisms. By analyzing alterations in metabolic pathways in the brain tissues of ischemic stroke patients, it is possible to identify the most influential metabolic routes and offer new insights for the discovery of therapeutic targets. The metabolites identified can also serve as indicators used for early diagnosis and disease monitoring (Sidorov et al., 2019; Chumachenko et al., 2022; Li et al., 2023).

An exemplar recent multi-omics study by Li et al. (2020) delved into the molecular changes that occur during the progression of stroke and aimed to identify potential markers and drug targets for stroke treatment. The authors used the mice middle carotid artery occlusion (MCAO) model to simulate stroke and performed proteome profiling on cerebral cortex samples at various time points. Proteomic analysis revealed general upregulation of genes associated with immune response and downregulation of genes related to neurodevelopment throughout stroke progression. To further narrow down potential drug targets, the authors then conducted integrated transcriptomic analyses using multiple Gene Expression Omnibus (GEO) datasets for the same purpose and compared the results with findings from the proteomics data, and three proteins (C3, Apoa4, and S100a9) emerged as potential markers or drug targets for stroke as all three displayed significant upregulation in the MCAO model and the GEO datasets. These results again pointed to the involvement of the complement system in stroke progression and suggested that inhibiting C3 activity could be a potential therapeutic approach for mitigating inflammation and reducing brain injury after stroke. For more information on this topic, the review (Montaner et al., 2020) by Montaner et al. has specifically detailed how such omics-driven computational analyses could help to illuminate the intricate molecular landscape driving stroke progression and provide promising new avenues for targeted interventions in ischemic stroke treatment. We have also summarized in Table 3 recent representative omics-based studies with applications in ischemic stroke translational research.

On the network pharmacology side, Casas et al. (2019b) used a bottom-up “target-to-data” approach and chose NOX4 (NADPH oxidase 4), a potent producer of superoxide following the onset of ischemic stroke, as the primary protein target to study potential combination therapies for stroke. The authors employed network pharmacology approaches for multi-omics datasets and identified four targets—CYBB (cytochrome B-245 beta chain), NOS2 (nitric oxide synthase 2), NOS3 (nitric oxide synthase 3), and NOS1 (nitric oxide synthase 1) that potentially have synergistic interaction with NOX4. Subsequently, NOS family was selected for experimental validation, and the authors showed that in vitro cultured brain cells treated with the NOX4 inhibitor (GKT136901) plus the NOS inhibitor (L-NAME) exhibited superior cell survival compared to the control group (single inhibitor) after oxygen-glucose deprivation. This significant combination effect was further demonstrated in tMCAO mice in vivo, suggesting that such a network pharmacology and omics-driven approach could be of great value in deciphering multi-target drug discovery and therapy for ischemic stroke.

As reviewed and discussed here, a number of computational models have been developed to describe the multilevel changes that occur during ischemic stroke, encompassing cellular, tissue, and systems-level alterations within the human body. These computational studies have utilized various types of modeling approaches to analyze and predict numerous quantifiable aspects of the disease, such as changes in blood flow, the extent of infarction, radiological alterations, and clinical indicators. However, each modeling approach has its own advantage and limitation. Omics-driven network pharmacology modeling and analysis are capable of handling vast amounts of biological data in a comprehensive and multi-level manner, and thus it can facilitate efficient and cost-effective screening of therapeutic targets compared to traditional biological experiments. However, this sort of modeling analysis demands high quality experimental data, which means incomplete or low-quality data can result in low-accuracy and biased outcomes (Aderem, 2005; Martin et al., 2011; Somvanshi and Venkatesh, 2014; Meyer and Saez-Rodriguez, 2021). Mechanism-based systems biology models often have rich information regarding signaling pathways and cellular crosstalk; still, establishing association between biological markers and clinical endpoints is always a challenge for neurological disorders. Physics-based models can vividly illustrate the physical changes in cerebral blood flow and the alterations in brain electrical signal conduction following an ischemic stroke. However, they rarely account for the related pathophysiological signal transduction or biological regulatory mechanisms. Therefore, integrating multiple modeling approaches (mechanism-based, physics-based, omics-based) in ischemic stroke research can ideally allow for the combination of their strengths and thereby significantly drive model-based translational applications in various aspects including identification of new therapeutic targets, simulation of clinical trials, design of personalized surgical plans, and prediction of stroke recovery. Such a multi-scale modeling strategy has already demonstrated significant potential in various other disease areas (Zhang et al., 2021; Zhao C. et al., 2022; Zhao C. et al., 2023), so we envision that its application in ischemic stroke will greatly facilitate basic research and translational medicine.

Another emerging computation-intensive research direction in ischemic stroke is machine learning, a branch of artificial intelligence designed to analyze large datasets automatically and make data-driven decisions (Jhaveri et al., 2022; Jabeen et al., 2023). In a recent study by Nishio et al. (2020), deep learning algorithms were applied to construct a model that can assist physicians in analyzing clinical CT images from stroke patients. The authors used existing CT imaging data from ischemic stroke patients to train a two-stage deep learning model, and the resulting model demonstrated outstanding assistive capacities in real clinical scenarios in terms of providing fast and accurate diagnosis according to automatic analysis of patient CT images. In another study by Brugnara et al. (2020), a machine learning model was constructed to predict individualized treatment outcomes for ischemic stroke patients. The study incorporated clinical diagnosis and imaging data as well as treatment outcome data (modified Rankin Scale scores) spanning 3 years for 246 ischemic stroke patients. According to their treatment outcomes, patients were categorized into favorable and unfavorable groups, and a machine learning model based on gradient-boosted classifier was used for prediction. Their results show that the trained machine learning model can accurately predict patient outcomes 3 months post-treatment and identify specific patient characteristics that may lead to unfavorable treatment results. In summary, we envision that in future the aforementioned systems-level modeling strategies, particularly when combined with machine learning, will have increasingly significant roles throughout the diagnosis and treatment of ischemic stroke and hold great promise as high-throughput computational tools in the development of new drug targets and therapeutics.